CLVS.Q Overzicht aandelen
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 0/6 |
| Dividenden | 0/6 |
Clovis Oncology, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$0.015 |
| 52 Week Hoogtepunt | US$2.87 |
| 52 Week Laag | US$0.01 |
| Bèta | 0.66 |
| 11 maand verandering | -40.00% |
| 3 maanden verandering | -28.57% |
| 1 Jaar Verandering | -99.39% |
| 33 jaar verandering | -99.77% |
| 5 jaar verandering | -99.97% |
| Verandering sinds IPO | -99.88% |
Recent nieuws en updates
Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10
Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31
Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05Rendement voor aandeelhouders
| CLVS.Q | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 18.1% | -1.3% | -1.6% |
| 1Y | -99.4% | 19.1% | 30.1% |
Rendement versus industrie: CLVS.Q presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 19.1 % opleverde.
Rendement versus markt: CLVS.Q presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.1 % opleverde.
Prijsvolatiliteit
| CLVS.Q volatility | |
|---|---|
| CLVS.Q Average Weekly Movement | 61.3% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.0% |
Stabiele aandelenkoers: De aandelenkoers van CLVS.Q is de afgelopen 3 maanden volatiel geweest.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van CLVS.Q is het afgelopen jaar gestegen van 39% naar 61%.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2009 | 413 | Patrick Mahaffy | www.clovisoncology.com |
Clovis Oncology, Inc. Samenvatting
| CLVS.Q fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$2.18m |
| Inkomsten(TTM) | -US$251.91m |
| Inkomsten(TTM) | US$133.02m |
0.0x
P/S-verhouding0.0x
Koers/WinstverhoudingIs CLVS.Q overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CLVS.Q resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$133.02m |
| Kosten van inkomsten | US$31.59m |
| Brutowinst | US$101.43m |
| Overige uitgaven | US$353.33m |
| Inkomsten | -US$251.91m |
Laatst gerapporteerde inkomsten
Sep 30, 2022
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -1.73 |
| Brutomarge | 76.25% |
| Nettowinstmarge | -189.37% |
| Schuld/Eigen Vermogen Verhouding | -158.0% |
Hoe presteerde CLVS.Q op de lange termijn?
Bekijk historische prestaties en vergelijking